Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | PTGIR | P43119 | 1/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21076157 | 0.94 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1PTGDR2CYP3A4 | |
| SCHEMBL17124779 | 0.91 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1PTGDR2CYP3A4 | |
| SCHEMBL6281909 | 0.90 | CYP1A2 (0.64) | ALDH1A1MAPK1L3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL14768422 | 0.89 | HTT (0.52) | ALDH1A1MAPK1L3MBTL1PTGDR2 | |
| SCHEMBL17124773 | 0.87 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1CYP2C9TBXA2R | |
| SCHEMBL31530756 | 0.86 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1PTGDR2CYP3A4 | |
| SCHEMBL6366353 | 0.86 | NPC1 (0.59) | ALDH1A1MAPK1L3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL6081043 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MAPK1L3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL17130188 | 0.84 | L3MBTL1 (0.47) | ALDH1A1MAPK1L3MBTL1PTGDR2CYP3A4 | |
| SCHEMBL5151754 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753599-B1 | BIPHENYL COMPOUNDS FOR USE IN TREATING MALARIA AND OTHER PARASITIC DISORDERS | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2019-06-05 | — | — | EP | disclosed |
| US-9499471-B2 | Biphenyl compounds for use in treating malaria and other parasitic disorders | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2016-11-22 | — | — | US | disclosed |
| US-9499471-B2 | Biphenyl compounds for use in treating malaria and other parasitic disorders | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2016-11-22 | — | — | US | disclosed |
| US-20150274637-A1 | BIPHENYL COMPOUNDS FOR USE IN TREATING MALARIA AND OTHER PARASITIC DISORDERS | GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150274637-A1 | BIPHENYL COMPOUNDS FOR USE IN TREATING MALARIA AND OTHER PARASITIC DISORDERS | GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER (DE) | 2015-10-01 | — | — | US | disclosed |
| WO-2013034756-A1 | BIPHENYL COMPOUNDS FOR USE IN TREATING MALARIA AND OTHER PARASITIC DISORDERS | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274637-A1 | BIPHENYL COMPOUNDS FOR USE IN TREATING MALARIA AND OTHER PARASITIC DISORDERS | CYP1B1, CYP1A2, CYP1A1 | ALDH1A1 75/4885MAPK1 4676/4885L3MBTL1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.